Cargando…
Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086292/ https://www.ncbi.nlm.nih.gov/pubmed/36720582 http://dx.doi.org/10.1136/ard-2022-223406 |
| _version_ | 1785022119280640000 |
|---|---|
| author | Dougados, Maxime Charles-Schoeman, Christina Szekanecz, Zoltán Giles, Jon T Ytterberg, Steven R Bhatt, Deepak L Koch, Gary G Vranic, Ivana Wu, Joseph Wang, Cunshan Kwok, Kenneth Menon, Sujatha Connell, Carol A Yndestad, Arne Rivas, Jose L Buch, Maya H |
| author_facet | Dougados, Maxime Charles-Schoeman, Christina Szekanecz, Zoltán Giles, Jon T Ytterberg, Steven R Bhatt, Deepak L Koch, Gary G Vranic, Ivana Wu, Joseph Wang, Cunshan Kwok, Kenneth Menon, Sujatha Connell, Carol A Yndestad, Arne Rivas, Jose L Buch, Maya H |
| author_sort | Dougados, Maxime |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10086292 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | BMJ Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-100862922023-04-12 Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme Dougados, Maxime Charles-Schoeman, Christina Szekanecz, Zoltán Giles, Jon T Ytterberg, Steven R Bhatt, Deepak L Koch, Gary G Vranic, Ivana Wu, Joseph Wang, Cunshan Kwok, Kenneth Menon, Sujatha Connell, Carol A Yndestad, Arne Rivas, Jose L Buch, Maya H Ann Rheum Dis Letter BMJ Publishing Group 2023-04 2023-01-31 /pmc/articles/PMC10086292/ /pubmed/36720582 http://dx.doi.org/10.1136/ard-2022-223406 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
| spellingShingle | Letter Dougados, Maxime Charles-Schoeman, Christina Szekanecz, Zoltán Giles, Jon T Ytterberg, Steven R Bhatt, Deepak L Koch, Gary G Vranic, Ivana Wu, Joseph Wang, Cunshan Kwok, Kenneth Menon, Sujatha Connell, Carol A Yndestad, Arne Rivas, Jose L Buch, Maya H Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme |
| title | Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme |
| title_full | Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme |
| title_fullStr | Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme |
| title_full_unstemmed | Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme |
| title_short | Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme |
| title_sort | impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086292/ https://www.ncbi.nlm.nih.gov/pubmed/36720582 http://dx.doi.org/10.1136/ard-2022-223406 |
| work_keys_str_mv | AT dougadosmaxime impactofcardiovascularriskenrichmentonincidenceofmajoradversecardiovasculareventsinthetofacitinibrheumatoidarthritisclinicalprogramme AT charlesschoemanchristina impactofcardiovascularriskenrichmentonincidenceofmajoradversecardiovasculareventsinthetofacitinibrheumatoidarthritisclinicalprogramme AT szekaneczzoltan impactofcardiovascularriskenrichmentonincidenceofmajoradversecardiovasculareventsinthetofacitinibrheumatoidarthritisclinicalprogramme AT gilesjont impactofcardiovascularriskenrichmentonincidenceofmajoradversecardiovasculareventsinthetofacitinibrheumatoidarthritisclinicalprogramme AT ytterbergstevenr impactofcardiovascularriskenrichmentonincidenceofmajoradversecardiovasculareventsinthetofacitinibrheumatoidarthritisclinicalprogramme AT bhattdeepakl impactofcardiovascularriskenrichmentonincidenceofmajoradversecardiovasculareventsinthetofacitinibrheumatoidarthritisclinicalprogramme AT kochgaryg impactofcardiovascularriskenrichmentonincidenceofmajoradversecardiovasculareventsinthetofacitinibrheumatoidarthritisclinicalprogramme AT vranicivana impactofcardiovascularriskenrichmentonincidenceofmajoradversecardiovasculareventsinthetofacitinibrheumatoidarthritisclinicalprogramme AT wujoseph impactofcardiovascularriskenrichmentonincidenceofmajoradversecardiovasculareventsinthetofacitinibrheumatoidarthritisclinicalprogramme AT wangcunshan impactofcardiovascularriskenrichmentonincidenceofmajoradversecardiovasculareventsinthetofacitinibrheumatoidarthritisclinicalprogramme AT kwokkenneth impactofcardiovascularriskenrichmentonincidenceofmajoradversecardiovasculareventsinthetofacitinibrheumatoidarthritisclinicalprogramme AT menonsujatha impactofcardiovascularriskenrichmentonincidenceofmajoradversecardiovasculareventsinthetofacitinibrheumatoidarthritisclinicalprogramme AT connellcarola impactofcardiovascularriskenrichmentonincidenceofmajoradversecardiovasculareventsinthetofacitinibrheumatoidarthritisclinicalprogramme AT yndestadarne impactofcardiovascularriskenrichmentonincidenceofmajoradversecardiovasculareventsinthetofacitinibrheumatoidarthritisclinicalprogramme AT rivasjosel impactofcardiovascularriskenrichmentonincidenceofmajoradversecardiovasculareventsinthetofacitinibrheumatoidarthritisclinicalprogramme AT buchmayah impactofcardiovascularriskenrichmentonincidenceofmajoradversecardiovasculareventsinthetofacitinibrheumatoidarthritisclinicalprogramme |